What is pgd

Medical Purpose and Applications

Preimplantation Genetic Diagnosis (PGD) is an advanced reproductive medicine technique that enables couples to identify genetic abnormalities in embryos before pregnancy begins. The procedure is typically used in conjunction with in vitro fertilization (IVF), where multiple embryos are created in the laboratory. By analyzing the genetic composition of these embryos, reproductive specialists and parents can make informed decisions about which embryos to transfer into the uterus. PGD serves two primary purposes: preventing transmission of known genetic diseases and improving IVF success rates by selecting chromosomally normal embryos.

Technical Process

The PGD process begins with standard IVF procedures, where eggs are fertilized in the laboratory and allowed to develop to the blastocyst stage, approximately five to six days after fertilization. A small number of cells (typically 5-10) are extracted from the outer cell layer of the developing embryo using a technique called biopsy. These cells are then analyzed through various genetic testing methods including fluorescence in situ hybridization (FISH), comparative genomic hybridization (CGH), or next-generation sequencing (NGS). The genetic analysis provides detailed information about chromosomal structure and specific gene mutations present in each embryo.

Disease Screening Capabilities

PGD can identify numerous genetic conditions, broadly categorized into monogenic diseases (single-gene disorders) and chromosomal abnormalities. Common monogenic conditions screened include:

• Cystic fibrosis, characterized by lung and pancreatic dysfunction
• Sickle cell disease, affecting red blood cell structure and function
• Huntington's disease, causing progressive neurological degeneration
• Hemophilia, a blood clotting disorder
• Muscular dystrophy variants affecting muscle function

Chromosomal screening (PGS/PGT-A) detects abnormal chromosome numbers like trisomy 21 (Down syndrome), which significantly improves pregnancy viability and reduces miscarriage risk.

Clinical Benefits and Success Rates

PGD significantly improves outcomes for couples with known genetic disease history or advanced maternal age. For individuals carrying genetic mutations, PGD reduces disease transmission risk from nearly 50% to less than 1% when unaffected embryos are selected. IVF success rates improve substantially when only chromosomally normal embryos are transferred, particularly for women over 35 where chromosomal abnormalities increase substantially. Studies demonstrate that PGD-selected embryos have higher implantation rates, lower miscarriage rates, and improved delivery outcomes compared to unselected embryo transfers.

Ethical and Social Considerations

PGD raises significant ethical questions about genetic selection and the definition of disease. While screening for serious life-threatening conditions generally receives broader acceptance, debates continue regarding screening for less severe conditions, predisposition to diseases, or non-medical traits. Disability rights advocates express concerns that genetic screening may reinforce discriminatory attitudes toward individuals with genetic conditions. Different countries and ethical frameworks establish varying guidelines regarding acceptable screening criteria, reflecting cultural values and religious perspectives on genetic selection and reproductive autonomy.